STUDY ON CAUSE–EFFECT RELATIONS AND OPTIMIZATION OF EXEMESTANE-LOADED NANOSTRUCTURED LIPID CARRIERS
DOI:
https://doi.org/10.22159/ijpps.2017v9i5.17354Keywords:
Exemestane, Optimization, NLC, BCPharSoft OPT softwareAbstract
Objective: Exemestane is an anti-breast cancer drug, possesses low water solubility and low permeability. This work aimed at the cause-effect relations and optimization of exemestane-loaded nanostructured lipid carriers (EXE-NLCs) for oral delivery.
Methods: Excipient screening was based on exemestane solubilities and the emulsification efficiency of surfactants. A D-optimal design based on three independent variables was applied to evaluate the cause-effect relations and optimise EXE-NLCs formulation. The particle size (PS), polydispersity index (PDI), entrapment efficiency (EE) and drug loading (DL) were investigated with respect to three independent variables including liquid lipid to total lipid ratio (X1), surfactant concentration (X2), total lipid concentration (X3).
Results: EXE-NLCs were prepared by a hot sonication method employing Labrafac CC and Compritol 888ATO as liquid and solid lipids, respectively, and Cremophor RH40 as a surfactant and Lutrol E-400 as a co-surfactant. All investigated factors: liquid lipid to total lipid ratio, surfactant concentration and total lipid concentration showed significant influences on physicochemical characteristics of EXE-NLCs. The optimal EXE-NLC formulation was composed of liquid lipid to total lipid ratio (X1) of 24 % (w/w), surfactant concentration (X2) of 4 % (w/v) and total lipid concentration (X3) of 4 % (w/v). The PS, PDI, EE and DL of the optimized EXE-NLCs were found to be 41.787 nm; 0.11; 97.605 % and 1.935 %, respectively. The optimized formulation was experimentally examined which demonstrated a good agreement between experimental and predicted values.
Conclusion: The cause-effect relations and optimization of EXE-NLCs were investigated and reported for the first time. EXE-NLCs formulation was successfully optimized using D-optimal design and merits further study.
Downloads
References
Deeks ED, Scott LJ. Exemestane: a review of its use in postmenopausal women with breast cancer. Drugs 2009;69:889-918.
Suzuki T, Miki Y, Nakamura Y, Moriya T, Ito K, Ohuchi N, et al. Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer 2005;12:701-20.
Singh AK, Chaurasiya A, Singh M, Upadhyay SC, Mukherjee R, Khar RK. Exemestane loaded self-micro emulsifying drug delivery system (SMEDDS): development and optimization. AAPS PharmSciTech 2008;9:628-34.
Hiremath PS, Soppimath KS, Betageri GV. Proliposomes of exemestane for improved oral delivery: formulation and in vitro evaluation using PAMPA, Caco-2 and rat intestine. Int J Pharm 2009;380:96-104.
Kumar A, Sawant K. Encapsulation of exemestane in polycaprolactone nanoparticles: optimization, characterization, and release kinetics. Cancer Nanotechnol 2013;4:57-71.
Li Z, Liu K, Sun P, Mei L, Hao T, Tian Y, et al. Poly(D, L-lactide-co-glycolide)/montmorillonite nanoparticles for improved oral delivery of exemestane. J Microencapsul 2013;30:432-40.
Srinivas P, Sumapriya T. Exemestane loaded polymeric nanoparticles for oral delivery. Int J Nano Dimens 2014;5:539-48.
Rane SS, Anderson BD. What determines drug solubility in lipid vehicles: is it predictable? Adv Drug Delivery Rev 2008;60:638-56.
Porter CJ, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilization using lipid-based delivery systems. Adv Drug Delivery Rev 2008;60:673-91.
Doktorovova S, Souto EB. Nanostructured lipid carrier-based hydrogel formulations for drug delivery: a comprehensive review. Expert Opin Drug Delivery 2009;6:165-76.
Ghadi R, Dand N. BCS class IV drugs: highly notorious candidates for formulation development. J Controlled Release 2017;248:71-95.
Jenning V, Thünemann AF, Gohla SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 2000;199:167-77.
Souto EB, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004;278:71-7.
Kavitha K, Kanagathara N. Optimization and solubilization study of novel nanoemulsion formulation for 5-fluorouracil by applying pseudoternary phase diagram. Asian J Pharm Clin Res 2014;7:137-9.
Tzachev CT, Svilenov HL. Lipid nanoparticles at the current stage and prospects: a review article. Int J Pharm Sci Rev Res 2013;18:103-15.
Shaji J, Shaikh M. Formulation, optimization, and characterization of biocompatible inhalable D-cycloserine-loaded alginate-chitosan nanoparticles for pulmonary drug delivery. Asian J Pharm Clin Res 2016;9:82-95.
Zhang W, Li X, Ye T, Chen F, Sun X, Kong J, et al. Design, characterization, and in vitro cellular inhibition and uptake of optimized genistein-loaded NLC for the prevention of posterior capsular opacification using response surface methodology. Int J Pharm 2013;454:354-66.
Pradhan M, Singh D, Murthy SN, Singh MR. Design, characterization and skin permeating potential of Fluocinolone acetonide loaded nanostructured lipid carriers for topical treatment of psoriasis. Steroids 2015;101:56-63.
Araujo J, Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Optimization and physicochemical characterization of triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int J Pharm 2010;393:168-76.
Chaudhary S, Garg T, Murthy RS, Rath G, Goyal AK. Development, optimization and evaluation of long chain nanolipid carrier for hepatic delivery of silymarin through lymphatic transport pathway. Int J Pharm 2015;485:108-21.
Ferreira M, Chaves LL, Lima SA, Reis S. Optimization of nanostructured lipid carriers loaded with methotrexate: a tool for inflammatory and cancer therapy. Int J Pharm 2015;492:65-72.
Gonzalez-Mira E, Egea MA, Souto EB, Calpena AC, GarcÃa ML. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Nanotechnology 2010;22:045101.
Jain K, Sood S, Gowthamarajan K. Optimization of artemether-loaded NLC for intranasal delivery using central composite design. Drug Delivery 2015;22:940-54.
Pokharkar VB, Shekhawat PB, Dhapte VV, Mandpe LP. Development and optimization of eugenol loaded nanostructured lipid carriers for periodontal delivery. Int J Pharm Pharm Sci 2011;3:138-43.
Phatak AA, Chaudhari PD. Development and evaluation of nanostructured lipid carrier (NLC) based topical delivery of an anti-inflammatory drug. J Pharm Res 2013;7:677-85.
Shah M, Agrawal Y. Development of ciprofloxacin HCl-based solid lipid nanoparticles using ouzo effect: an experimental optimization and comparative study. J Dispersion Sci Technol 2013;34:37-46.
Yang CR, Zhao XL, Hu HY, Li KX, Sun X, Li L, et al. Preparation, optimization and characteristic of huperzine loaded nanostructured lipid carriers. Chem Pharm Bull 2010;58:656-61.
Aslam M, Aqil M, Ahad A, Najmi AK, Sultana Y, Ali A. Application of box–behnken design for the preparation of glibenclamide loaded lipid-based nanoparticles: optimization, in vitro skin permeation, drug release and in vivo pharmacokinetic study. J Mol Liq 2016;219:897-908.
Kumbhar DD, Pokharkar VB. Engineering of a nanostructured lipid carrier for the poorly water-soluble drug, bicalutamide: physicochemical investigations. Colloids Surf A 2013;416:32-42.
Mandpe L, Pokharkar V. Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement. Pharm Dev Technol 2015;20:320-9.
Zhang X, Liu J, Qiao H, Liu H, Ni J, Zhang W, et al. Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol 2010;197:120-8.
Published
How to Cite
Issue
Section
